My office phone is (b)(6) and my cell phone is (b)(6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: jnjournals@jamanetwork.org <jnjournals@jamanetwork.org>
Sent: Wednesday, January 22, 2020 9:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: JAMA article JVP200006 ready for editing

01-22-2020

Dear Dr Fauci,

Please confirm receipt of this email as soon as possible.

Your manuscript, "Coronavirus Infections: More Than Just the Common Cold" (JVP200006), is entering the editing process. You will receive an edited typescript, including editors' queries, from a JAMA manuscript editor very soon. Responses to the manuscript editor will be due 24 hours from contact. A few days after that, a proof will be sent to you for final review and approval.

If you have a mobile phone number that we can use to reach you, please send that to me. Please do your best to respond as thoroughly and quickly as possible.

Should you plan to be traveling during the next couple of weeks and not able to access email, please let me know immediately and please identify the name and contact information (email address and phone number) of your backup. We look forward to working with you.

Sincerely,

NIH-002775
Carmina Conley
JAMA

Confidentiality Note: This communication, including any attachment, is solely for the use of the addressee(s), may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.
Sorry. Here they are. This is what happens when you have 600 e-mails in your inbox.

Updated CoV slides

BG

**********************************************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: 
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
From: Petra Lernö Hagaskolan
Sent: Saturday, January 25, 2020 3:50 AM
To: Fauci, Anthony (NIH/NIAID) [E]<
Subject: Coronavaccine

Hi!
I saw that you are working with a coronavirus vaccine. I studied Masters in Infection biology and tried a new non toxic adjuvant for mucosal immunisation as my Masters thesis. I delivered plasmids into the cell with a non toxic adjuvant and it had full access to the nucleus. It gave antibodies both in serum and in the mucosa.
It was my own project but I was not allowed to continue with my research.

Best regards

Petra Lernö,
Lärare åk 7-9
Biologi
Matematik

Hagaskolan
Dals- Eds kommun
Besöksadress
Gamla Edsvägen 46
668 30 Ed

Postadress;
Box 30
668 21 Ed

E- post
Barney:

As per Jon Cohen's questions, have you officially requested the virus? If not, you should so that we can say that we did indeed try to obtain it. Will you answer Jon Cohen's question?
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health:
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon Cohen <jcohen@aaas.org>
Sent: Friday, January 10, 2020 4:33 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
Subject: Wuhan coronavirus

Hi Barney and Tony,

Has the NIH requested the Wuhan coronavirus sequence from China?

If so, when, and what has been the response?

Thanks,
Jon
As discussed.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-5000  
FAX: (301) 496-4408  
E-mail: fauci@nih.gov  
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

Hi Dr Fauci and Dr Marston.  
Attached is your Viewpoint on the n-CoV. We would really like to publish it tomorrow morning.  
Is it possible for you to review very quickly today? In the next hour or 2?  

Thanks so much  
Stacy

Stacy L. Christiansen, MA  
Managing Editor, JAMA  
Chair, AMA Manual of Style
Thanks.

-----Original Message-----
From: Corey MD, Larry
Sent: Sunday, January 26, 2020 3:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Coronavirus

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, January 25, 2020 5:55 PM
To: Corey MD, Larry <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Coronavirus

-----Original Message-----
From: Corey MD, Larry <(b) (6)>
Sent: Saturday, January 25, 2020 8:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus

Sent from my iPhone
The outline looks good – 

From: Paules, Catharine
Sent: Saturday, January 11, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Subject: Coronaviruses are cool
I have not responded. Please take care of this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Thanks a million.

May Dr. Ashton and I come to DC Monday afternoon to record some development of the potential vaccine and interview you?
What might we be able to capture on camera?

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: 212-456-2016
Connect on Social: T/I/F = @ericMstrauss
From: Fauci, Anthony (NIH/NIAID) [mailto:] (b) (6)
Sent: Wednesday, January 29, 2020 10:45 PM
To: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) Billet, Courtney (NIH/NIAID) [E]
Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Eric:

The CDC is holding people for 3 days since that will give them the opportunity to question the level of risk to which they were exposed and also, their nasal passages will be tested for virus. If they have symptoms they go to tertiary follow-up of a closer medical exam. If they have no symptoms and their medical exam is negative they will be go home with instructions to monitor themselves carefully. There is reluctance to keep people for 15 days when they have a negative diagnostic test and they are in the loop of being self-monitored.

I am sure that we can arrange to have Dr. Ashton come to our vaccine research center to witness the actual research of the vaccine.

Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Wednesday, January 29, 2020 3:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Fwd: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Hello Dr Fauci. I thought the joint press conference yesterday was great. Very clear information.

Especially your guidance in asymptomatic spread in relation to previous outbreaks and it’s minor impact.

- please see my colleagues questions below. Why are they keeping the US citizens isolated for only 3 days if the incubation period has been reported between a day and 14? May I quote your answer or just for my background knowledge?

- I have a standing request with HHS and CDC about bringing Dr Ashton and a crew to see the preparedness / on going response... do you have any visual ideas what we can do to educate and reassure the US public? Anything about diagnostic, therapy or vaccine development?

________________________________________
Eric M. Strauss, ABC News
Managing Editor, Medical Unit
212-456-2016
@ericMstrauess
Begin forwarded message:

From: "Finnegan, Conor J."<Conor.J.Finnegan@abc.com>
Date: January 29, 2020 at 2:15:37 PM EST
To: "Strauss, Eric M."<Eric.M.Strauss@abc.com>
Subject: Re: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Random medical Q... if the incubation period is 14 days, why aren’t they holding everyone from the flight for 14 days? If they’re infected, they wouldn’t necessarily show signs after 3 days—so they could potentially be releasing infected people right?

Conor Finnegan | ABC News State Dept Reporter-Producer | Cell: | Sent from my iPhone

On Jan 29, 2020, at 2:08 PM, Strauss, Eric M.<Eric.M.Strauss@abc.com> wrote:

UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Media Statement

For Immediate Release
Wednesday, January 29, 2020

Contact: CDC Media Relations
(404) 639-3286

   UPDATED: HHS and CDC receive flight carrying repatriated US citizens

This morning, the Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC) in collaboration with the Department of State received the flight carrying approximately 210 U.S. citizens from Wuhan at March Air Reserve Base in California.

The plane was met by a team of CDC medical officers deployed there to assess the health of the passengers. The passengers have been screened, monitored and evaluated by medical personnel every step of the way, including before takeoff, during the flight, during a refueling in Anchorage, Alaska, and now post-arrival. CDC staff have conducted risk assessments to ensure the health of each traveler, including temperature checks and observing for respiratory symptoms.
CDC will work with the California Department of Public Health and Riverside County Public Health to transport any passenger exhibiting symptoms to a hospital for further evaluation. Passengers not exhibiting symptoms of exposure, will be asked to stay on the base in housing to allow CDC medical officers to perform more thorough screening and to better understand each individual’s exposure.

CDC is committed to protecting the health and safety of Americans. At this time, we continue to believe the risk of coronavirus exposure to the general public is low. CDC is taking these measures to assess and care for these returning Americans to protect them, their loved ones, and their communities.


###

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**

*CDC works 24/7 protecting America’s health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.*
Let us discuss. Doubt if I have time for this.

From: Anjana Nair
Sent: Sunday, January 26, 2020 3:51 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Request for Interview Regarding Novel Coronavirus

Sir,

My name is Anjana Jayakrishnan Nair and I am currently a student of Journalism and Mass Communication at Kerala University in South India.

We are doing a semester-wise lab journal and I am in charge of the science page. One of articles is on the coronavirus epidemic. Reuters reported talk of a vaccine for it. If it is not an inconvenience, could you give us some details on that? It would be a great honour to quote you directly in an article.

Thanking you,

Anjana J Nair
Thanks. Very helpful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

The Global Research Collaboration for Infectious Diseases (GloPID-R) convened to discuss the Wuhan coronavirus situation this morning. GloPID-R is a consortium of funders for EID research; we are not permanent members (b)(3). Call was held this morning to accommodate global time zones.

Participants: WHO R&D Blueprint, NIH, EC, BMGF, INSERM, Institut Pasteur, ISARIC, GOARN China is not part of GloPID-R (though they have been invited). South Korea and Thailand are, and were invited but were unable to join.

Situation update (from WHO):
- Wuhan cluster information unchanged – 41 cases, 1 death; investigations ongoing for a zoonotic source. Based on sequencing info, it appears to be a single source (with some minor variation based on sequencing methodology). Importantly, when market was closed live animals were moved and likely not carefully tracked.
• **Confirmed case in Thailand**, identified by sequencing. Patient resides in Wuhan and traveled to Thailand. Exposure history is being investigated — whether in market or not. She was identified and isolated January 8 and is doing well.

• **Sequences deposited in GenBank**, apparently **NOT to be used for countermeasure development** as stipulated when submitted.

Research priorities (from WHO):

1. **Diagnostics**: WHO held an expert call on Saturday (I believe Vincent participated?). Discussing development of diagnostics outside of China, which is critical for preparedness. Marion Kaufmann convened group.

2. **Therapeutics and vaccines** — similar to prior report. Preparing landscape analysis; prioritizing products to be tested; adjusting existing clinical protocols used for MERS.

3. WHO will present funders with a research plan. Clearly an expectation that funders would support (we often do “in kind”/noting research we fund as contributions). Also need staff support.

Data sharing: a key priority; group thankful that sequences are being deposited, even with those restrictions.

Reorienting existing projects: EC, IHR, NIH all reaching out to coronavirus investigators regarding potential interest in work on this virus.
Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4049
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dr. Fauci,
I hope you are well. You regaled the leadership of the business-ngo U.S. Global Leadership Coalition over dinner in July of 2017, and we are requesting your expertise again at a time of deep concern for the country and the world.

Our nationwide network of veterans, returned Peace Corps volunteers, Rotary Club members, global health professionals, faith leaders, state and local Chamber presidents, and elected officials are obviously concerned about reports of the Coronavirus from China. They have been asking us for the latest on the virus and how our civilian international capabilities are up to the task on this matter and on other global health security issues to come.

Would you be able to join us from your office for a nationwide conference call on the Coronavirus for 30-45 minutes for any of these windows during the week of February 10:

- February 10 | 2:30pm – 3:30pm EST
- February 11 | 2:00pm – 5:00 pm EST
- February 12 | 2:00pm – 6:00pm EST
February 13 | 4:00pm – 6:00pm EST

We’ll build our call around your availability! We know how much your time is in demand, but you can reach thousands of influential community leaders – deeply interested in global affairs – during our call. We would be so grateful if you could find 45 minutes in two weeks to join us.

Thank you so much and don’t hesitate to contact me with any questions,

Jason
Jason J. Gross | Executive Director | (b) (6) | p: (b) (6)
U.S. Global Leadership Coalition | 1129 20th Street NW, Suite 600, Washington, DC 20036 | @USGLC

From: Jason Gross (b) (6)
Sent: Thursday, July 20, 2017 4:44 PM
To: (b) (6)
Cc: Lindsay Lee Plack (b) (6)
Subject: Thank you for joining us last evening

Dr. Fauci,

On behalf of the entire U.S. Global Leadership Coalition, Lindsay and I want to thank you for anchoring our dinner last night with key members of our leadership. Immediately after the dinner last night and spilling into today, we have received heartfelt, positive feedback from your remarks last night. Our members are not only wiser after sitting down with you for an evening, but they were also reassured and proud that you worked at the fulcrum of so many public health challenges our nation has faced over the past decades.

Equally importantly, the conversation last night served to reinforce our coalition’s determination to educate and advocate for the resources for pro-active American leadership in global health and related initiatives. Whether it was your recounting of the unforeseen resilience of Nigeria’s Ebola resistance after PEPFAR investments a decade earlier, the remarkable story of advances in AIDS treatment due to private sector research and development, or the residual challenges in multilateral coordination for global health challenges we must address, your words rang true with our participants and provided them with ideas and arguments to press forward.

Please do not hesitate to call on us if we can provide any assistance to you in the future, and thank you again for your remarkable service to our country. We hope our paths cross again soon in the future.

Yours,
Jason Gross
Executive Director
U.S. Global Leadership Coalition

Lindsay Lee Plack
Government Relations Director
U.S. Global Leadership Coalition
Please take a look at this.

From: Dr. Hugo Manly <(b)[(b)]>
Sent: Tuesday, January 28, 2020 1:25 AM
To: Bolan, Gail (CDC/DDID/NCHHSTP/DSTDHP) [(b)](6)
Cc: Fauci, Anthony (NIH/NIAID) [(b)](6)
Subject: Corona Virus Vaccine

Doctors in France believe a vaccine can be made with CD 21 and CD83, combined with the DPT vaccine, since most of the Orientals in that region lack that, at least those who have fallen victim to the Coronavirus.

The Wuhan Dept of Health is very lax and will not respond to this data, but, Xi Jinping’s assistants, are eager to have more data from us, which your offices have reviewed and followed up on with supportive, technical information, since they have no DPT formulation data now, and they do not make up CD83 correctly and he knows it.

Dr. Hu Manly
Jack:
  Thank you for your kind note. I hope that all is well with you.
Best regards,
Tony

Tony:

Just reading the latest coronavirus-news out of China, and it looks as if you could be the most-important man in the world within the foreseeable future.

If so, mankind couldn't be in better hands.

I don't think I ever mentioned it, The two of you could possibly wind-up in the forefront of any pandemic that might evolve, should the virus elude the PRC's exceptional effort at containment.

Nobleheartedly,

Jack
Print out for PCC folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] <broadway@nih.gov>
Sent: Friday, January 10, 2020 5:10 PM
To: NIAID OD AM <NIAIDODAM@nih.gov>
Cc: Bushar, Nicholas (NIH/NIAID) [E] <broadway@nih.gov>
Subject: Wuhan coronavirus overview

With input from divisions and budget, Nick and I put together the attached brief overview of our existing (mainly MERS) coronavirus work. I will also put in disease info.

Hilary D. Marston, MD, MPH
Medical Officer and Policy Advisor for Global Health
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
Cell: (b) (6)
Email: (b) (6)
Barry:

A travel history is the best way to go. The Chinese had person-to-person spread in the first week of December and did not realize that they had any infections with a new virus until Dec. 31, 2019. Then then thought that it was all animal to human. We they finally figured out that the virus spread human to human, the horse was already out of the barn.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Hi Tony.....

Question for you,

...my clinic just put out a note to all Nursing & Front Desk staff about the period of time that person can be infected with the Coronavirus ... be potentially contagious, and yet exhibit no symptoms ...as being 1-14 days. I think that’s pretty close to accurate, ...but we didn’t talk much about stuff like this during Lynn’s bedside patient rounds in Bldg. 10.
I see from the major news channel coverage that airport officials (and others) seem to be making initial screenings of large numbers of people (at airports, etc.) using infrared forehead temp guns.

What do you think the false negative rates might be with these infrared guns for head temps measurements, especially for asymptomatic yet coronavirus infected people,...and should we, at our Clinic (being on the West Coast), be a bit more inquisitive and pro-active ....re: asking where patients coming into our clinic have been and if they have been in the company of others who have been traveling to and from China, ....or other SE Asian countries?

Then, ....what exactly happened in Wuhan that started all of this?

I pay top-dollar for answers like this!

Barry

---

From: Fauci, Anthony (NIH/NIAID) [E] [mailto:]
Sent: Friday, January 17, 2020 1:50 PM
To: Barry Albertson
Subject: RE: Hi from Ore

Barry:

Thanks for the note. All is well here. I hope the same for you. Great photo! Thanks for sending it.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Hi Tony,
... saw you last night on our local PBS station talking about Ebola, ..nicely done as usual.
Do you ever get any rest?
Hope you’re well and holding up. DC (i.e. the Capitol building) seems to be a really happening place these days!!
Note sure if I send this to you, but attached is the group photo of the 1970-1990 ERRB/DEB group at our reunion last March...Lynn is seated front/center...probably didn’t need to tell you that,...I’m in the back row near center.
Barry
Ps - Lynn turns 60 in a few months, but still hospital bedside rounding with Medicine/Endocrinology med students, Residents & Fellows !! You and he seem to be cut from the same cloth!
From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Tuesday, January 28, 2020 6:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: urgent news overnight

Good morning, Tony,
These both published in the past hour.
Can you talk right away?
Many thanks.
Elizabeth


Coronavirus patient in **Germany** is a 33-year-old German citizen

From CNN's Stephanie Halsaz

The **coronavirus** patient in Germany has been identified as a 33-year-old German man who works in Starnberg, south of Munich. He had not been to China but was in a meeting with a Chinese national last week, who has since been identified with the coronavirus. Dr. Andreas Zapf, the head of the Bavarian State Office for Health and Food safety said Tuesday.

Zapf said at a news conference that the patient had attended a company meeting in Starnberg last week, where the training manager -- a female Chinese citizen -- was leading the meeting. The Chinese staff member is originally from Shanghai, but her parents had visited her there a few days prior to the meeting in Germany, Zapf said.

The Chinese citizen has since flown back to China. She felt ill on the flight back and tested positive for the coronavirus after her return to Shanghai. She notified the German office upon this discovery, Zapf said.

The first three European cases of Wuhan coronavirus were identified in France on Friday.
First suspected case of human-to-human transmission of novel coronavirus in Japan

From CNN's Junko Ogura and Yoko Wakatsuki in Tokyo

Customers buy face masks from a drugstore in Tokyo's Akihabara district. Charly Triballeau/AFP/Getty Images

Japan’s health ministry confirmed two additional cases of the novel coronavirus on Tuesday, bringing the total number of confirmed cases in the country to six.

The sixth patient -- a man in his 60s in western Japan -- has no history of visiting Wuhan, but is a bus driver who drove tour groups from the central Chinese city for nine days, according to the health ministry.

This is the first case of suspected human-to-human transmission in Japan from someone who did not travel to Wuhan.

On Sunday, China announced a ban on outbound group travel as part of measures to stop the spread of the Wuhan coronavirus.

Elizabeth Cohen, MPH
CNN Senior Medical Correspondent
Am tied up right now. Will call a little later.

Has to do with this - copy and paste of the pertinent paragraph below. Ma is the Chinese health minister. This reporting appears to be accurate – CNN has it as well.

Ma said the incubation period for the coronavirus can range from one to 14 days, and that the virus is infectious during incubation, which was not the case with Severe Acute Respiratory Syndrome (SARS), a coronavirus that originated in China and killed nearly 800 people globally in 2002 and 2003.

https://www.reuters.com/article/us-china-health-transmission-idUSKBN1ZP09G
Cristina:

I am drowning here with coronavirus stuff and I am starting to get these types of e-mails. I do not have time to respond to them and so I will be forwarding them to you. Use your judgment in your response, try to help if appropriate, and as always in the spirit of NIAID, be sensitive, polite and your usual charming self. 😊

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4440
E-mail: 

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
This is Steven GONG from Clover Biopharma. I am writing to inform you that Clover has started development of a recombinant coronavirus (2019-nCoV) S-protein subunit-trimer vaccine using our globally-patented Trimer-Tag platform, and we would like to seek your advice and see if there are any potential collaboration opportunities with NIAID. Clover is a global, clinical-stage and VC-backed biopharmaceutical company, and our novel & proprietary Trimer-Tag® Technology platform can be used produce covalently-trimerized fusion proteins to target trimerization-dependent pathways. As you are aware, the Spike (S) glycoprotein of 2019-nCoV from WUHAN CHINA forms a trimer on the viral envelope.

We have completed gene-synthesis of our 2019-nCoV subunit-trimer vaccine, and plan to have the vaccine material ready for further preclinical evaluation in February 2020. Given that Clover has I have attached a brief introduction to Clover, Trimer-Tag, and our Subunit-Trimer Vaccines. Let us know if any further questions.

I hope that Clover’s innovative subunit-trimer vaccines platform could be of some help in assisting CDC/NIAID in rapidly developing a viable coronavirus vaccines. We will keep you posted on our progress on this as more data will be come out in next couple of weeks, and we appreciate your comments on our approach and

Steven GONG

Clover Biopharmaceuticals
Rafe:

Great to hear from you. I hope that you are well. This very intense. should touch bases again some time when things settle down. I will fill you in on where I am.

Best regards,

Tony

---

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

---

From: Rafe Sagalyn
Sent: Thursday, January 30, 2020 9:36 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: --

Hello Tony - What a time this must be for you.

A new client (b) (6) told me about (b) (6) George Scangos who, like you, is appearing on news programs to explain how serious this virus is. I figure you know Scangos and his new company VIR

Thank you for doing what you do.
P.S. (b)(6) have had the best possible news of late — not one but two grandchildren. They’re in Seattle this weekend seeing baby (b)(6).

P.P.S. Those WHO stats below are fascinating how they put things into context

On Jan 30, 2020, at 12:45 AM, (b)(6) wrote:

Had no idea that the infection rates were so high for measles. Yikes. Thanks for sending along.

(b)(6) George Scangos on the coronavirus outbreak from CNBC this morning:


(b)(6)

vg # of people infected by an individual w/ the following Measles 12-18 infected Smallpox 5-7 Polio 5-7 Mumps 4-7 HIV/AIDS 2-5 SARS-CoV 2-5 Influenza 2-3 *Coronavirus 1.4-2.5 (current outbreak) Ebola 1.5-2.5

via WHO
See responses in red below

From: ZHANG SHENG <zsheng@u.edu>
Sent: Tuesday, January 28, 2020 4:12 AM
To: Fauci, Anthony (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Questions to your new article "Coronavirus Infections more than just the common cold"

Dear Prof. Anthony S. Fauci:

My name is Sheng Zhang, a research fellow at a Chinese University. I just read your article about the new type Coronavirus infections, and have some questions. Sincerely appreciate that if you can answer them to clear some of my doubts.

The questions are:

1. Is the vaccine ready and approved by FDA?

2. Did you get the virus sample?

3. What do you think about this outbreak of Coronavirus infections in China? And based on which judgement?

I sincerely appreciate that if you can briefly answer these questions. Looking forwards to your reply.

Best regards,

---
Sheng (Shawn) Zhang

Tsinghua University
State Key Laboratory of Tribology
Beijing 100084, China
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 15:33:50 +0000
To: Jon LaPook
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Greg Folkers [b] [b]; Billet, Courney (NIH/NIAID) [E]
Subject: RE: Thanks so much, Tony. Two more questions.

John:
Thanks for the note. As you said, I will be in town tomorrow. I have my NIAID Advisory Council from 10:30 to 11:45 AM and some other things that I need to do during the day, but I am sure that Patty Conrad can do her magic and figure out a way that we can do an interview. In that regard, please make sure that you copy her on all communications (she is copied here). You have my cell number. Her office number is (b) (6) and her cell number is (b) (6). I look forward to speaking with you.

Best regards,
Tony

-----Original Message-----
From: Jon LaPook <(b) (6)>
Sent: Sunday, January 26, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] 
Subject: Re: Thanks so much, Tony. Two more questions.

Thanks, Tony,
I'm in LA and coming back a day early so I can do a piece on coronavirus tomorrow (Monday). Now that you will be in town, I wonder if I should fly to DC today rather than NYC, and interview you Monday morning or early afternoon. Are you available?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 26, 2020, at 4:30 AM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Jon:
They are still trying to figure out the R0. I have heard 1.5 to 2.5, but I have not seen data. If asked, I would say that we just do not know at this point. At first we were saying 2 to 4 days and now the Chinese Health Minister is saying 14 days. I think that this is still an evolving question.

Best,
Tony

-----Original Message-----
From: Jon LaPook <(b) (6)>
Sent: Saturday, January 25, 2020 10:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] 
Subject: Thanks so much, Tony. Two more questions.

1) Any sense of the R0?
2) Do you think the incubation period is 2-14 days?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook
I am sorry that I did not get back to you. I am swimming in coronavirus stuff.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
Fax: (301) 496-4409  
E-mail: fauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Hi Dr Fauci

I'm working on a story on the flu's impact on children this year. Do you have a few minutes to talk tomorrow? Let me know best # and time. Thanks. I'm free 9 am to 1:30 pm.

Best,

Sumathi

---

Sumathi Reddy
The Wall Street Journal
"Your Health" columnist
I think that we will be OK.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Is it too similar to ours? I just read it and there are similarities for sure but if the focus is more on the need for prototype pathogens I think we may be ok?
As per our plans for a commentary

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-0772
FAX: (301) 496-4409
E-mail: fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folgers, Greg (NIH/NIAID) [E]
Sent: Wednesday, January 15, 2020 6:16 PM
Subject: International Journal of Infectious Diseases: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China
http://bit.ly/30mm2It

International Journal of Infectious Diseases
Available online 14 January 2020
In Press, Journal Pre-proof
What are Journal Pre-proof articles?

Editorial
The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China

Author links open overlay panel

David S. Hui

Esmail Azhar1, A. Madani, Francine Ntoumi, Richard Kock1, Osman Dar, Giuseppe Pirolo, Timothy D. Mchugh1, Ziad A. Memishab, Christian Drostenabc, Alimuddin Zumla1, Eskild Petersenab

https://doi.org/10.1016/j.ijid.2020.01.009 Get rights and content

Under a Creative Commons license

open access

The city of Wuhan in China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a novel coronavirus. In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei province in China, with an epidemiological link to the Huanan Seafood Wholesale Market where there was also sale of live animals. Notification of the WHO on 31 Dec 2019 by the Chinese Health Authorities has prompted health authorities in Hong Kong, Macau, and Taiwan to step up border surveillance, and generated concern and fears that it could mark the emergence of a novel and serious threat to public health (WHO, 2020a, Parr, 2020).

The Chinese health authorities have taken prompt public health measures including intensive surveillance, epidemiological investigations, and closure of the market on 1 Jan 2020. SARS-CoV, MERS-CoV, avian influenza, influenza and other common respiratory viruses were ruled out. The Chinese scientists were able to isolate a novel CoV from a patient within a short time on 7 Jan 2020 and perform genome sequencing of the novel CoV. The genetic sequence of the novel CoV has become available to the WHO on 12 Jan 2020 and this has facilitated the laboratories in different countries to produce specific diagnostic PCR tests for detecting the novel infection (WHO, 2020b). The novel CoV is a β CoV of group 2B with at least 70% similarity in genetic sequence to SARS-CoV.

SARS is a zoonosis caused by SARS-CoV, which first emerged in China in 2002 before spreading to 29 countries/regions in 2003 through a travel-related global outbreak with 8,098 cases with a case fatality rate of 9.6%. Nosocomial transmission of SARS-CoV was common while the primary reservoir was bats and the intermediary source was civet cats in the wet markets in Guangdong (Hui and Zumla, 2019).

MERS is a novel lethal zoonotic disease of humans endemic to the Middle East, caused by MERS-CoV. Humans are thought to acquire MERS-CoV infection though contact with camels or camel products with a case fatality rate close to 35% while nosocomial transmission is also a hallmark (Azhar et al., 2019). The recent outbreak of clusters of viral pneumonia due to a novel CoV in the Wuhan market poses significant threats to international health and may be related to sale of wild animal as game food at the seafood market.

As of 10 Jan 2020, 41 patients have been diagnosed to have infection by the novel CoV. The onset of illness of the 41 cases ranges from 8 December 2019 to 2 January 2020. Symptoms include fever (>90% cases), malaise, dry cough (80%), shortness of breath (20%) and respiratory distress (15%). The vital signs were stable in most of the cases while leucopenia and lymphopenia were common. Among the 41 cases, six patients have been discharged, seven patients are in critical care and one died, while the remaining patients are in stable condition. The fatal case involved a 61 year-old man with an abdominal tumour and cirrhosis who was admitted to a hospital due to respiratory failure and severe pneumonia.

The diagnoses included severe pneumonia, acute respiratory distress syndrome, septic shock and multi-organ failure. The novel CoV infection in Wuhan appears clinically milder than SARS or MERS overall in terms of severity, case fatality rate and transmissibility. There is currently no clear evidence of human to
human transmission. At present, 739 close contacts including 419 healthcare workers are being quarantined and monitored for any development of symptoms (WHO, 2020b, Center for Health Protection and HKSAR, 2020). No new cases have been detected in Wuhan since 3 January 2020. However, the first case outside China has been reported today, 13th January 2020 in a Chinese tourist visiting Thailand, who is being treated in hospital.

The Chinese Health Authorities have carried out very appropriate and prompt response measures including active case finding, and retrospective investigations of the current cluster of patients which have been completed; The Huanan Seafood Wholesale Market has been temporarily closed to carry out investigation, environmental sanitation and disinfection; Public risk communication activities have been carried out to improve public awareness and adoption of self-protection measures. Technical guidance on novel coronavirus has been developed and will continue to be updated as additional information becomes available.

However, many questions about the new coronavirus remain. While it appears to be transmitted to humans via animals, the specific animals and other reservoirs need to be identified, the transmission route, the incubation period and characteristics of the susceptible population and survival rates. At present, there is however very limited clinical information of the novel CoV infection and data are missing in regard to the age range, animal source of the virus, incubation period, epidemic curve, viral kinetics, transmission route, pathogenesis, autopsy findings and any treatment response to antivirals among the severe cases. Once there is any clue to the source of animals being responsible for this outbreak, global public health authorities should examine the trading route and source of movement of wild animals from other parts to Wuhan and prevent further such trade which is posing risk to human health. The rapid identification and containment of a novel coronavirus virus rapidly in a short period of time (phylogenetic tree: Archive Number: 20200012.6885385) is a re-assuring and commendable achievement by China’s public health authorities and reflects the increasing global capacity to detect, identify, define and contain new outbreaks.

This outbreak brings back memories of of the novel coronavirus outbreak in China, the severe acute respiratory syndrome (SARS) in China in 2003, caused by a novel SARS-CoV-coronavirus (World Health Organization, 2019a). SARS-CoV rapidly spread from southern China in 2003 and infected more than 3,000 people, killing 774 by 2004, and then disappeared - never to be seen again. However, The Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) (World Health Organization, 2019b), a lethal zoonotic pathogen that was first identified in humans in the Kingdom of Saudi Arabia (KSA) in 2012 continues to show up through intermittent sporadic cases, community clusters and nosocomial outbreaks. Between 2012 and December 2019, a total of 2465 laboratory-confirmed cases of MERS-CoV infection, including 850 deaths (34.4% mortality) were reported from 27 countries to WHO, the majority of which were reported by KSA (2073 cases, 772 deaths). Whilst several important aspects of MERS-CoV epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, have been defined, there remain many unanswered questions, including source, transmission and epidemic potential. The Wuhan outbreak is a stark reminder of the continuing threat of zoonotic diseases to global health security. More funder and governmental investments are required for a more concerted and collaborative global effort, learning from experiences from all geographical regions, through a ‘ONE-HUMAN-ENVIRONMENTAL-ANIMAL-HEALTH’ global consortium to reduce the global threat of zoonotic diseases (Zumla et al., 2016).

Author declarations
All authors have a specialist interest in emerging and re-emerging pathogens. FN, OD, GI, CD are members of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020
Framework Programme for Research and Innovation. AZ has received a National Institutes of Health Research senior investigator award. All authors declare no conflicts of interest.

References

WHO, 2020a

WHO Emergencies preparedness, response. Pneumonia of unknown origin – China Disease outbreak news (2020)
5 January, Accessed 12 Jan 2020. Available at:
Google Scholar

Parr, 2020

J. Parr Pneumonia in China: lack of information raises concerns among Hong Kong health workers
BMJ, 368 (2020), p. m56, 10.1136/bmj.m56
Published 8 January 2020
Google Scholar

WHO, 2020b

WHO Emergencies preparedness, response. Pneumonia of unknown origin – China Disease outbreak news (2020)
12 January, Accessed 12 Jan 2020. Available at:
Google Scholar

Hui and Zumla, 2019

DSC Hui, A Zumla Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features
Article
Download PDFView Record in ScopusGoogle Scholar

Azhar et al., 2019

Al Azhar, DSC Hui, ZA Memish, C Drosten, A. Zumla The Middle East Respiratory Syndrome (MERS)
Article
Download PDFView Record in ScopusGoogle Scholar

Center for Health Protection and HKSAR, 2020

Center for Health Protection, HKSAR Press Release
11 Jan Accessed 12 Jan 2020. Available at:
Google Scholar

World Health Organization, 2019a

World Health Organization SARS (Severe Acute Respiratory Syndrome)
- accessed 12th January, 2020
Google Scholar

World Health Organization, 2019b

World Health Organization MERS situation update
(accessed August 20, 2019)

Google Scholar

Zumla et al., 2016

A Zumla, O Dar, R Kock, et al. Taking forward a ‘One Health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential
Int J Infect Dis, 47 (2016), pp. 5-9

Article
Download PDFView Record in ScopusGoogle Scholar

Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

View Abstract
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Please take care of this as you have done in the past. Thanks.

---

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Tuesday, January 28, 2020 7:09 AM
To: As Sy Elhadj; Brundtland Gro Harlem; Dzau Victor; Chris Elias; Farrar Jeremy; Fauci, Anthony (NIH/NIAID) [E]; Fora Henrietta; Gao Fu; Gashumba Diane; Kaag Sigrid; Ilona Kickbusch; Suzuki Yasuhiro; Vega Morales Jeanette; Vega Morales Jeanette; VijayRaghavan Krishnaswamy; 'Skvortsova Veronika'
Cc: MAHJOUR, Jaouad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard; Alex Harris; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esved Marja; Gonggrijp Mette; Julie.HALL; Kanarek Morgan; Marston, Hilary (NIH/NIAID) [E]; Omar Abdi; Amelie RIOUX; Tore Godal; GABEDAVA, Tsira; ROSS, Alex; Banks Lynn; Block Bruce; Conrad Jane; Conrad, Patricia (NIH/NIAID) [E]; Del Sol Dinia; Diao Fay; Gahungu Zacharie; Harikumar M K; Kebagire Christine; KITA Yosuke; Steven T. Smith; Miller de Vega Teresa; MURIUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Be mir; YU Bai; Kirsi Madi; 'Oleg Sonin'

Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Importance: High

Dear Board members,

Thank you to all who participated in yesterday’s teleconference call regarding the novel 2019-Coronavirus outbreak.
We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries’ (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than **1700 Wednesday 29 January, Geneva time**

Thank you very much.

Kinds regards,

Gro and As
From: [Redacted]
Sent: Thu, 30 Jan 2020 20:45:42 -0500
To: Cassetti, Cristina (NIH/NAID) [E]
Subject: Fwd: The Coronavirus & Peptide BioSciences' Immune Complex Inhibitor

Please handle

Begin forwarded message:

From: Lisa [Redacted]
Date: January 30, 2020 at 7:16:15 PM EST
To: "Fauci, Anthony (NIH/NAID) [E]"
Cc: [Redacted]
Subject: The Coronavirus & Peptide BioSciences' Immune Complex Inhibitor
Eric:

Thanks for the note. The reports from China that it can spread from asymptomatic people are troubling. I have not seen the data and so I really cannot figure out how strong the science is. We really need to have our own CDC be allowed to go to China to see the data. The drugs that have shown in pre-clinical studies to “possibly” have some activity against corona viruses are remdesivir, which is a drug that we tested in DRC against Ebola. It did not work very well against Ebola, but people are considering using it for nCoV. This is not an anti-HIV drug. The other drug, which is an anti-HIV drug, is Kaletra. It is a combination of two drugs: lopinavir and ritonavir. Given the fact that there are no proven drugs to treat this coronavirus, it is understandable that they are using Kaletra on a compassionate basis. If someone is seriously ill with the virus, there is little down-side to using it. It may not help, but it unlikely will hurt. My cell number is (b)(6).

Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Sunday, January 26, 2020 9:46 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Returning Home Safety

Thx for checking back in.

Do you think the reports from Chinese that it can spread in asymptomatic is based in science?

What do you make of using HIV meds?

Would you pls trust us with your cell? Dr Ashton wanted to ask you something private and didn’t save your number from last week. Promise not to bother you too often.
On Jan 25, 2020, at 9:04 PM, Fauci, Anthony (NIH/NIAID) wrote:

The Lancet paper established that people who are infected can have no symptoms. They made the implication without evidence that people without symptoms (asymptomatic) can transmit the infection despite the fact that they are not clinically ill. There is no solid evidence at this time that this is the case.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Saturday, January 25, 2020 7:04 PM
To: Fauci, Anthony (NIH/NIAID)
Subject: Re: Returning Home Safety

That’s exactly what I’m asking! Thank you so much. And thanks for answering on a Sat night!

Dr Ashton and I and ABC News have been aggressively trying to keep everyone calm in our reporting.

Especially unless there is any human to human spread discovered in the US.

What do you make of the early Lancet studies showing a few of the people didn’t have respiratory symptoms? Just GI... probably more about poor reporting but Chinese clinicians than true on-set right?

-EMS
C:
On Jan 25, 2020, at 6:48 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Eric:
   Thanks for the note.

   I hope that this is helpful.

Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Saturday, January 25, 2020 11:46 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Returning Home Safety

Dear Dr. Fauci:

Thank you as always for your reasonable perspective in putting ID in context. The important precautions you recommend and pointing out that this is a travers disease was so important for our coverage at ABC News!
Eric M. Strauss, Managing Editor
ABC News, Medical Unit
@ericMstrauss
212-456-2016
eric.m.strauss@abc.com
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 03:03:52 +0000
To: Erbelding, Emily (NIH/NIAID) [E]
Subject: FW: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma

Emily:
We need to chat about your email address.
Tony

From: Microsoft Outlook <MicrosoftExchange329e329e71ec88e4615b36e4615b36ab6ce41109e@mail.nih.gov>
Sent: Wednesday, January 22, 2020 5:29 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Undeliverable: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma

Delivery has failed to these recipients or groups:

The email address you entered couldn’t be found. Please check the recipient’s email address and try to resend the message. If the problem continues, please contact your helpdesk.

Diagnostic information for administrators:
Generating server: uccbx03.nih.gov

Remote Server returned '550 5.1.1 RESOLVER.ADR.RecipientNotFound; not found'

Original message headers:

Received: from uccbx03.nih.gov (156.40.79.152) by uccbx03.nih.gov
(156.40.79.152) with Microsoft SMTP Server (TLS) id 15.0.1473.3; Wed, 22
Jan 2020 17:28:59 -0500
Received: from GCC02-DM3-obe.outbound.protection.outlook.com (156.40.79.134)
by uccbx02.nih.gov (156.40.79.152) with Microsoft SMTP Server (TLS) id
15.0.1473.3 via Frontend Transport; Wed, 22 Jan 2020 17:28:59 -0500
Received: from SN6PR09MB3664.namprd09.prod.outlook.com (52.132.113.14) by
SN6PR09MB3664.namprd09.prod.outlook.com (20.177.252.29) with Microsoft SMTP
From: "Fauci, Anthony (NIH/NIAID) [E1]" (fauci. anthony@nih.gov)
To: "Cassetti, Cristina (NIH/NIAID) [E]"
CC: "Marston, Hilary (NIH/NIAID) [E]"
Subject: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma
Thread-Topic: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma
Thread-Index: AdXREhagqeqTqYcGTRGhmmayqFapq9/gAYNX9A
Importance: high
X-Priority: 1
Date: Wed, 22 Jan 2020 22:28:57 +0000
Message-ID: <SN6PR9MB3758A55FC141F73C88EE045B990C08SN6PR9MB3758.namprd09.prod.outlook.com>
References: <007701cd6d12864d3401d479e708@cloverbiopharma.com> In-Reply-To: <007701cd6d12864d3401d479e708@cloverbiopharma.com>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach: yes
X-MS-TNEF-Correlator:
authentication-results: niaid.nih.gov; dkim=none (message not signed)
header.d=niaid.nih.gov; dmarc=none action=none
header.from=niaid.nih.gov;
x-originating-ip: [156.40.216.11]
x-ms-publictraffic: Email
x-ms-office365-filtering-correlation-id: 8ed60c23-4feb-49f6-c22e-08d79f8a7901
x-ms-traffictypediagnostic: SN6PR9MB3664:
x-ms-oob-tlc-oobclassifiers: OLM=10000;
x-forefront-antispm-report: SPF:SKI;SFS;DIR:INB;SPF;SCL:-1;SRVR:SN6PR9MB3664;H:SN6PR9MB3758.namprd09.prod.outlook.com;FPR;SFF:None;
LANG:en;
x-microsoft-antispam: BCL:0;
x-microsoft-antispam-message-info:
83eFRBd72Dszg529tDc5ODK48G1P0zAHW4PajL1Pbt5Cc29ItilvCN0KDbhEvIGS8DfTszlJC3VFP/H4zWJXdbSsgsS32fZTWP/pJvdML1Qr+q1YPL3xui8gW+5VD4PvLPTyxeNHy1gHCLV+759x0NgYt97elZKXCEag6YfawvRKYKFTSTsxyXjeKIAhixtMhGnGd40zZj193Dmyq5u/8/E+peOBQOeflB/v2A9hPmW+p6S0iU2zYEmg9QT996BDdK4GLlEvWw6BfGzCzy3p2i1nXoa4IjGg09j7+bEk65oz0Rz3h1nPT1CkLAXA865vU+C2K54vGLY3NbympbD/q2bTf6BB47+6kJ7XSiCeOaEUVc0Meyyyk6sAFUFAhBog8d4WjgveNetza5KhrMhxBalfRBMsk8SGwMk02PcojY9j01a2qKa3s9R3x-microsoft-exchange-transport-forked: True
Content-Type: multipart/mixed;
boundary="_000_SN6PR9MB3758A55FC141F73C88EE045B990C08SN6PR9MB3758namp_
MIME-Version: 1.0
X-MS-Exchange-CrossTenant-Network-Message-Id: 8ed60c23-4feb-49f6-c22e-08d79f8a7901
(UTC)
As per our discussion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

See below. I honestly thought I had sent this back—but it got hung up. Sorry about that.
Please handle. Thanks.

-----Original Message-----
From: Al Abed, Yousef
Sent: Sunday, January 26, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Coronavirus: Potential treatment options

Dear Dr Anthony,

I have been involved in the field of drug discovery and sepsis for many years and I have two ideas that could be of interest to treat symptoms of coronavirus.

I am available to discuss it by phone or send it to you by an email.

Best,
Yousef

Yousef Al-Abed, PhD
The Feinstein Institute for Medical Research Northwell Health Manhasset, NY

The information contained in this electronic e-mail transmission and any attachments are intended only for the use of the individual or entity to whom or to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any dissemination, distribution, copying or disclosure of this communication and any attachment is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone and electronic mail, and delete the original communication and any attachment from any computer, server or other electronic recording or storage device or medium. Receipt by anyone other than the intended recipient is not a waiver of any attorney-client, physician-patient or other privilege.
OK. Take those out. Thanks.

They have now – looks like 15 mins for CDC, NIH and BARDA to do diagnostics, therapeutics and vaccines. I can take out the basic research and natural history slides. The others should work.

Just FYI they have not sent an agenda. I’m getting the slides weddle-ized, but it’s possible you won’t even present them.

Dear NIH Colleagues,

The agenda for tomorrow’s Novel Coronavirus Disaster Leadership Group includes one topic for NIH to speak to, therapeutics. Can you please confirm that at least one representative from NIH will participate in this DLG to speak to this issue? Please confirm attendance by emailing DLGDESK@hhs.gov.

Respectfully,

Kelsey Donnelly (CTR)
Jr. Management Analyst, Aveshka Inc.
Office of the Assistant Secretary for Preparedness and Response
Office of Strategy, Policy, Planning, and Requirements

HEALTH AND HUMAN SERVICES (DHHS) | O’Neill House Office Building | 200 C Street SW | Washington, DC

a: (b)(6) m: (b)(6)
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Jan 2020 21:02:50 +0000
To: Marston, Hilary (NIH/NIAID) [E]
CC: Greg Folkers (b)(6) Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Wuhan 2019-NCoV perspective

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b)(6)>
Sent: Saturday, January 18, 2020 1:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>
CC: Folkers, Greg (NIH/NIAID) [E] (b)(6)
Subject: Fwd: Wuhan 2019-NCoV perspective
Begin forwarded message:

From: "Munster, Vincent (NIH/NIAID) [E]" (b) (6)
Date: January 18, 2020 at 11:18:37 AM EST
To: "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>
Cc: "De wit, Emmie (NIH/NIAID) [E]" (b) (6)>
Subject: FW: Wuhan 2019-NCoV perspective

Hi Hilary,

Let me know what you think,

Vincent Munster, PhD
Chief, Virus Ecology Section
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH

From: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Date: Friday, January 17, 2020 at 6:14 PM
To: "NEJM Presubmission inquiries (b) (6)" NEJM Presubmission inquiries <presubmissioninquiries@nejm.org>
Subject: Re: Wuhan 2019-NCoV perspective

Vincent,
This could be of interest. Since you already have a draft, do you mind sharing as this will help me more rapidly assess the potential?

NIH-002032
From: "Munster, Vincent (NIH/NIAID) [E]" <vincent.munster@nih.gov>
Date: Friday, January 17, 2020 at 3:40 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>, NEJM Presubmission inquiries <presubmissioninquiries@nejm.org>
Subject: Wuhan 2019-NCov perspective

Dear Dr. Baden,

We would like to ask whether you think a perspective on Wuhan novel coronavirus (2019-NCov) is of interest for NEJM.

Given the current situation in China (and Thailand, Japan and potentially Singapore), we think this contribution is very timely.

The contribution will give a perspective on emerging coronavirus outbreaks, with an emphasis on the novel coronavirus 2019-NCov. Global public health communities are on high alert after the emergence of a novel coronavirus in Wuhan, China. The third novel emerging coronavirus in two decades, after SARS-CoV and MERS-CoV. So far, 48 cases have been reported in 3 countries (China, Thailand and Japan), including 2 fatalities and clear indications of human-to-human spread.

In our Perspective, we will argue that although it seems reassuring that the novel coronavirus appears to be much less pathogenic than MERS-CoV, and SARS-CoV, the threat of epidemic (or even pandemic) spread is likely larger than that of a more pathogenic virus. Infected people are still able to go to work and travel, thereby potentially spreading the virus. This is a huge risk to vulnerable populations with underlying comorbidities and healthcare settings, especially since SARS-CoV and MERS-CoV have shown a great propensity for nosocomial spread. Even though the virus may not be very pathogenic, this could result in a huge disruption of global public health systems and economic losses. In addition, identification of chains of transmission and subsequent contact tracing will be extremely hard in asymptomatic and mildly symptomatic cases. This warrants the current aggressive response aimed at tracing and diagnosing every infected patient and thereby breaking the transmission chain of this novel virus, so we don’t have to find out what its’ true epidemic or pandemic potential is.

The co-authors of this perspective have extensive experience in responding to emerging viruses, from SARS-CoV in 2003, highly pathogenic avian influenza H7N7, pandemic H1N1 influenza, MERS-CoV to the West African Ebola outbreak. The perspective is still a working draft, and is currently being reviewed by a number of co-authors and would be ready in the beginning of next week.

Kind regards,

Vincent Munster, PhD
Chief, Virus Ecology Section
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH

NIH-002833
This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.
Feng:

Thanks for the note. We would be happy to work with you to test the assays that you are developing. We ourselves are waiting for isolates and further sequence data. Happy to help you when we get these. The person at NIAID who would help with the development of the assays is Dr. Cristina Cassetti. She is copied here.

Best,
Tony

From: Feng Zhang
Sent: Sunday, January 26, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [b] (6)
Subject: Coronavirus detection

Dear Dr. Fauci,

Hope you are doing well.

I have been quite concerned about the coronavirus outbreak and have been working with colleagues to develop coronavirus testing based on our SHERLOCK technology. The technology allows for paper-strip based nucleic acid detection with single nucleotide differentiation.

I was wondering if you might be able to help us, or connect us with others, to get access to virus sequences or to partner with us to test the assays that we are developing?

Thank you very much!

Feng
Bob:

Thanks for the note. The CDC will designate hospitals in the Chicago area where suspect cases will be funneled. If you are not one of the designated hospitals it is unlikely that you will be referred patients. If you want to prepare for a true outbreak in the USA (unlikely), you should order typical Personal Protective Equipment (PPE) and have a isolation room, which you probably already have.

Best,
Tony

From: Geller, Robert D. <b>(b) (6)>
Sent: Wednesday, January 22, 2020 9:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <b>(b) (6)>
Subject: Coronavirus

Tony

Happy New Year. As I live and practice 100 miles west of O'Hare what precautions do we need to put in place relevant to coronavirus in the hospital or offices. Thank you.

Bob
Thanks, Greg.

Today's report from Wuhan has not yet hit. 
I suspect there will be more cases 
I will pull it and translate it when I get it—hopefully by hit time

Hannah Lovejoy
Planning Producer; CNN International
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: (6)

Dr Fauci will pretape at CNN studio at 1130 am ET today

**Topic:** discuss the new coronavirus pneumonia which is now known as the Wuhan virus.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.
Sent from my iPhone
From: Fauci, Anthony (NIH/NIARD) [E]
Sent: Fri, 31 Jan 2020 03:01:09 +0000
To: Jon LaPook
Subject: RE: TIME SENSITIVE: Wife to husband spread in Illinois.

Jon:

I am very sorry that I did not get to this in time. I was frozen in the Situation Room for hours. They do not allow iPhones in the Sit Room. I would nuance your statement a little bit. There are some who say that there is evidence of asymptomatic spread and so if you say there "is no evidence that people are contagious..." some compulsive person might call you on this. I would nuance it by saying that: "it is uncertain whether asymptomatic spread occurs." You are correct that we still do not know whether someone is contagious after their symptoms have resolved.

Best regards,
Tony

-----Original Message-----
From: Jon LaPook <b>(b) (6)>
Sent: Thursday, January 30, 2020 3:51 PM
To: Fauci, Anthony (NIH/NIARD) [E] <b>(b) (6)>
Subject: TIME SENSITIVE: Wife to husband spread in Illinois.

Hi Tony,

I'm about to be interviewed for tonight's segment. I plan to say that the math makes sense in terms of known incubation period (either 11 or 12 days assuming she wasn't contagious before symptoms). I also will say there's no evidence that people are contagious before they get symptoms, but we still do not know whether they might be contagious after their symptoms have resolved. Do I have this right?

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 28, 2020, at 6:28 AM, Fauci, Anthony (NIH/NIARD) [E] <b>(b) (6)>

No one knows right now since there are no studies examining viral shedding after clinical recovery. Another reason why I want our people on site. Having said that, we will know more with studies on the 5 patients who were here in the USA

-----Original Message-----
From: Jon LaPook <b>(b) (6)>
Sent: Monday, January 27, 2020 11:44 PM
To: Fauci, Anthony (NIH/NIARD) [E] <b>(b) (6)>
Subject: Re: Thanks, and one more question.

Any idea how long people are contagious once they stop having symptoms?

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

NIH-002839
On Jan 27, 2020, at 10:35 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

My pleasure!

-----Original Message-----
From: Jon LaPook [b] [9]
Sent: Monday, January 27, 2020 10:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [b] [9]
Subject: Re: Thanks, and one more question.

I will be on CBS This Morning at 8:15A tomorrow talking about coronavirus. We will use a bite from you to start it off. Thanks again, Tony.

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 27, 2020, at 8:47 PM, Fauci, Anthony (NIH/NIAID) [E] [b] [9] wrote:

Jon:
A surgical mask that one can purchase in a store and that you see so many Chinese people wearing in shots from China are certainly not perfect protectors against viral infections. They may be able to be of some benefit to block droplets from someone’s sneeze or cough. These droplets contain virus, and so there may be of some benefit. They also serve to prevent people from touching their nose and mouth, which is a way of spreading virus from your hand to your mucosal surfaces. I agree that people in the USA should not feel the need to wear masks on the subway right now.

Best,
Tony

-----Original Message-----
From: Jon LaPook [b] [9]
Sent: Monday, January 27, 2020 8:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [b] [9]
Cc: amb@cbsnews.com
Subject: Re: Thanks, and one more question.

Hi Tony,
I’m sure you’ve had a long, tough day (as usual). Would you mind taking a swing at the below question about the efficacy of wearing a surgical mask? And, believe it or not, They want me to address the question of whether people should wear a surgical mask on, say, the subway right now. My answer would be no. I would love you to back me up on that!

Thanks,
 Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 27, 2020, at 2:51 PM, Jon LaPook [b] [9] wrote:
Tony,
As always, I am so grateful for the terrific access we have to you and, more importantly, to your brain. One more question: how effective do you think these regular masks are – not the N95 ones but the masks you see people wearing on the street. On the one hand, the virus is so small it could go right through the mask. On the other hand, it might be effective in stopping droplets that contain virus. And in the Lancet article about the family cluster, the girl who wore the mask did not get sick whereas the 10-year-old boy who did not wear the mask did get sick.

Please keep us in the loop about new developments!

Best,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 16:27:38 +0000
To: carlschiller
Subject: RE: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Carl:

Thanks for the note. I hope that all is well with you. All good here. I anticipate that this new coronavirus from Wuhan will keep me busy for a while. If I get invited to the Aspen Ideas Festival this summer, I will shoot you an e-mail to see if we can connect.

Best regards,
Tony

From: carlschiller
Sent: Saturday, January 18, 2020 10:29 PM
To: Jim Stratton
Cc: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Pretty much what happens when you kill and eat anything that moves.

Calling on Tony Fauci (again).
I had lunch with Tony last year and told him he deserves the Nobel award. He laughed and said, No it was the other Italian kid Gallo who discovered the HIV virus, not him. Kind of reminded me of when Churchill was told that during the war he was the Lion for Britain. Churchill replied, the British people were the Lion, I was just privileged to deliver the roar.

On Jan 18, 2020, at 11:52 AM, James Stratton wrote:

Another bad coronavirus from China:

Begin forwarded message:

From: Centers for Disease Control and Prevention <no-reply@emailupdates.cdc.gov>
Date: January 17, 2020 at 19:38:10 PST
To: (b) (6)
Subject: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China
Reply-To: "Centers for Disease Control and Prevention" <subscriptions@cdc.gov>
Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Summary
The Centers for Disease Control and Prevention (CDC) continues to closely monitor an outbreak of a 2019 novel coronavirus (2019-nCoV) in Wuhan City, Hubei Province, China that began in December 2019. CDC has established an Incident Management System to coordinate a domestic and international public health response.

Coronaviruses are a large family of viruses. Some cause illness in people; numerous other coronaviruses circulate among animals, including camels, cats, and bats. Rarely, animal coronaviruses can evolve and infect people and then spread between people such as has been seen with Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) (https://www.cdc.gov/coronavirus/mers/index.html) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (https://www.cdc.gov/sars/index.html).

Chinese authorities report most patients in the Wuhan City outbreak have been epidemiologically linked to a large seafood and animal market, suggesting a possible zoonotic origin to the outbreak. Chinese authorities additionally report that they are monitoring several hundred healthcare workers who are caring for outbreak patients; no spread of this virus from patients to healthcare personnel has been reported to date. Chinese authorities are reporting no ongoing spread of this virus in the community, but they cannot rule out that some limited person-to-person spread may be occurring.

China has reported that two of the patients have died, including one with pre-existing medical
conditions. Chinese health officials publicly posted the genetic sequence of the 2019-nCoV on January 12, 2020. This will facilitate identification of infections with this virus and development of specific diagnostic tests.

Thailand and Japan have confirmed additional cases of 2019-nCoV in travelers from Wuhan, China. It is possible that more cases will be identified in the coming days. This is an ongoing investigation and given previous experience with MERS-CoV and SARS-CoV, it is possible that person-person spread may occur. There is much more to learn about the transmissibility, severity, and other features associated with 2019-nCoV as the investigations in China, Thailand, and Japan continue. Additional information about this novel virus is needed to better inform population risk.

This HAN Update provides a situational update and guidance to state and local health departments and healthcare providers that supersedes guidance in CDC’s HAN Advisory 424 distributed on January 8, 2020. This HAN Update adds guidance for evaluation of patients under investigation (PUI) for 2019-nCoV, prevention and infection control guidance, including the addition of an eye protection recommendation, and additional information on specimen collection.

Background

An outbreak of pneumonia of unknown etiology in Wuhan City was initially reported to WHO on December 31, 2019. Chinese health authorities have confirmed more than 40 infections with a novel coronavirus as the cause of the outbreak. Reportedly, most patients had epidemiological links to a large seafood and animal market. The market was closed on January 1, 2020. Currently, Chinese health authorities report no community spread of this virus, and no transmission among healthcare personnel caring for outbreak patients. No additional cases of infection with 2019-nCoV have been identified in China since January 3, 2020.

On January 13, 2020 public health officials in Thailand confirmed detection of a human infection with 2019-nCoV in a traveler from Wuhan, China. This was the first confirmed case of 2019-nCoV documented outside China. On January 17, 2020 a second case was confirmed in Thailand, also in a returned traveler from Wuhan City. On January 15, 2020 health officials in Japan confirmed 2019-nCoV infection in a returned traveler from Wuhan City. These persons had onset dates after January 3, 2020. These cases did not report visiting the large seafood and animal market to which many cases in China have been linked.


Recommendations for Healthcare Providers

Limited information is available to characterize the spectrum of clinical illness associated with 2019-nCoV. No vaccine or specific treatment for 2019-nCoV infection is available; care is supportive.

The CDC clinical criteria for a 2019-nCoV patient under investigation (PUI) have been developed based on what is known about MERS-CoV and SARS-CoV and are subject to change as additional information becomes available.

Healthcare providers should obtain a detailed travel history for patients being evaluated with fever and acute respiratory illness. CDC guidance for evaluating and reporting a PUI for MERS-CoV remains unchanged.

Criteria to Guide Evaluation of Patients Under Investigation (PUI) for 2019-nCoV

Patients in the United States who meet the following criteria should be evaluated as a PUI in association with the outbreak of 2019-nCoV in Wuhan City, China.

1) Fever\(^1\) AND symptoms of lower respiratory illness (e.g., cough, shortness of breath)
—and in the last 14 days before symptom onset,

- History of travel from Wuhan City, China
  -or-
- Close contact with a person who is under investigation for 2019-nCoV while that person was ill.
  2) Fever OR symptoms of lower respiratory illness (e.g., cough, shortness of breath)
  —and in the last 14 days before symptom onset,

- Close contact with an ill laboratory-confirmed 2019-nCoV patient.

The above criteria are also available at https://www.cdc.gov/coronavirus/2019-nCoV/clinical-criteria.html. The criteria are intended to serve as guidance for evaluation. Patients should be evaluated and discussed with public health departments on a case-by-case basis if their clinical presentation or exposure history is equivocal (e.g., uncertain travel or exposure).

Recommendations for Reporting, Testing, and Specimen Collection

Healthcare providers should immediately notify both infection control personnel at their healthcare facility and their local or state health department in the event of a PUI for 2019-nCoV. State health departments that have identified a PUI should immediately contact CDC’s Emergency Operations Center (EOC) at 770-488-7100 and complete a 2019-nCoV PUI case investigation form available at https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf. CDC’s EOC will assist local/state health departments to collect, store, and ship specimens appropriately to CDC, including during afterhours or on weekends/holidays. At this time, diagnostic testing for 2019-nCoV can be conducted only at CDC. Testing for other respiratory pathogens should not delay specimen shipping to CDC. If a PUI tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a PUI. This may evolve as more information becomes available on possible 2019 nCoV co-infections.

For biosafety reasons, it is not recommended to perform virus isolation in cell culture or initial characterization of viral agents recovered in cultures of specimens from a PUI for 2019-nCoV. To increase the likelihood of detecting 2019-nCoV infection, CDC recommends collecting and testing multiple clinical specimens from different sites, including all three specimen types—lower respiratory, upper respiratory, and serum specimens. Additional specimen types (e.g., stool, urine) may be collected and stored. Specimens should be collected as soon as possible once a PUI is identified regardless of time of symptom onset. Additional guidance for collection, handling, and testing of clinical specimens is available at https://www.cdc.gov/coronavirus/2019-nCoV/.

Interim Healthcare Infection Prevention and Control Recommendations for Patients Under Investigation for 2019-nCoV

Although the transmission dynamics have yet to be determined, CDC currently recommends a cautious approach to patients under investigation for 2019-nCoV (https://www.cdc.gov/coronavirus/2019-nCoV/clinical-criteria.html). Such patients should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private room with the door closed, ideally an airborne infection isolation room if available. Healthcare personnel entering the room should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield). Immediately notify your healthcare facility’s infection control department.
control personnel and local health department.

Additional Infection Control Practices Resources


Notes

1. Fever may not be present in some patients, such as those who are very young, elderly, immunosuppressed, or taking certain fever-lowering medications. Clinical judgment should be used to guide testing of patients in such situations.

2. Close contact with a person who is under investigation for 2019-nCoV. Close contact is defined as—

   a) being within approximately 6 feet (2 meters), or within the room or care area, of a novel coronavirus case for a prolonged period of time while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection); close contact can include caring for, living with, visiting, or sharing a healthcare waiting area or room with a novel coronavirus case.

   — or —

   b) having direct contact with infectious secretions of a novel coronavirus case (e.g., being coughed on) while not wearing recommended personal protective equipment.


Data to inform the definition of close contact are limited. Considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person with novel coronavirus (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special consideration should be given to those exposed in healthcare settings.

For More Information

More information is available at at https://www.cdc.gov/coronavirus/2019-ncov/index.html or by calling 800-CDC-INFO | (800-232-4636) | TTY: (888) 232-6348

The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

Categories of Health Alert Network messages:

Health Alert - Requires immediate action or attention; highest level of importance
Health Advisory - May not require immediate action; provides important information for a specific incident or situation

Health Update - Unlikely to require immediate action; provides updated information regarding an incident or situation

HAN Info Service - Does not require immediate action; provides general public health information

This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, HAN coordinators, and clinician organizations.

You have received this message based upon the information contained within our emergency notification database. If you have a different or additional e-mail or fax address that you would like us to use please contact your State-based Health Alert Network program at your State or local health department.

Centers for Disease Control and Prevention
1600 Clifton Rd  Atlanta, GA 30329  1-800-CDC-INFO (300-232-4636)  TTY: 888-232-6348

Questions or Problems  |  Unsubscribe
I will let you continue to deal directly with Hannah and so I will not reply to her. However, if they want to do Skype, David could get on the phone with me and school me on how to do Skype from my iPhone at home, which I have already done before with his help in my office. And so, you can tell Hannah that we are OK with Skype if the DC bureau cannot accommodate.

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10p ET.

If it isn’t, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.

Best,
Hannah

He will not need a car.

Also—to clarify—this will be a pre-tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That’s great—thank you Patricia.
Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: 19 January 2020 15:12  
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>  
Cc: Fauci, Anthony (NIH/NIAID) [E]  
Subject: Re: CNNi interview request - TDAY (Sunday 19th January)

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I’ve spoken to show producers and they need Dr Fauci this evening for a pre-tape — sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: 19 January 2020 14:59  
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>  
Cc: Fauci, Anthony (NIH/NIAID) [E]  
Subject: Re: CNNi interview request - TDAY (Sunday 19th January)

Washington DC.

Sent from my iPhone
On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci’s availability – what CNN studio will he be available from?

I will speak to my producers and confirm availability ASAP.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: 19 January 2020 14:39  
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>  
Cc: Fauci, Anthony (NIH/NIAID) [E]  
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: 19 January 2020 13:57  
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you're well.

I wanted to introduce myself, I'm Hannah Lovejoy and I'm a planning producer for CNN International.

We were hoping that you would be available to join us for a one-on-one interview today (Sunday 19th January)?

We'd like you to discuss the new coronavirus pneumonia which is now known as the Wuhan virus.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you're available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, CNN International
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: 03 69 |
Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.
From: Prabhala, Rao (b) (6)>
Sent: Thursday, January 30, 2020 9:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: coronavirus vaccine monitoring

Dear Dr. Fauci,

Best,
Dr. Rao Prabhala
DFCI/BWH/HMS

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.
Jon:

Very nice segment. Sorry that I did not get back to you myself today. As patty probably told you, I was completely tied up with meetings.

Best regards,

Tony

-----Original Message-----
From: Jon LaPook
Sent: Tuesday, January 28, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID)
Subject: Link to tonight's segment. Thanks again, Tony.


Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook
I have gone over the script remarks and the Council slides. The remarks are now marked as "FINAL" in the OD folder. However, I have kept the tracked changes showing so that you can see what I have done. Please accept these changes and then give it a spell and grammar check and it will be "FINAL". I have labelled the Council slides as "1st FINAL" since there are a few slides which I have indicated that will need to be updated (one of the influenza slides and the coronavirus slides) at the end of the coming week. After we do that, it will be "FINAL".

Thanks.

Dr. Fauci,

The Council Remarks and Council Slide DRAFTS for 01-27-2020 are ready for your review in G:OD. There are likely more slides than you need, but I tried to group them for potential culling.

Just as a reminder, we have no second speaker for Council this time.

Thank you,

Laurie

Laurie K. Doepel
Senior Advisor for Science Communications
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
9000 Rockville Pike
Building 31, Suite 7A03
Bethesda, MD 20892-2520
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:16:39 +0000
To: Aaron Weddle
Cc: 'john@vsbassociates.com';Greg Folkers;Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: POTUS briefing

Aaron:

Please make the usual 5 X 7 black framed photo of this with Legend: Briefing President trump on the 2019-nCoV (coronavirus) outbreak – The White House Situation Room – Jan. 29, 2020. Also, make a power point of this with the same title and Greg: please put th4 slide with our accumulating set of coronavirus slides.

Thanks,
Tony

---

From: Hall, Bill (HHS/ASPA) [b] [b]
Sent: Thursday, January 30, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] [b] [b]
Subject: POTUS briefing

Hi Tony...came across this shot from the collection from yesterday’s briefing. Thought you’d like to have a copy. Best, Bill
Wendy:
Thank you for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----
From: Wendy Holman
Sent: Tuesday, January 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Recent events

Hi there,

I continue to be endlessly impressed with the level of poise and sophistication coming from you and your NIAID staff regarding all of the questions and concerns relating to this recent coronavirus outbreak. I admire your level headed straight shooter approach to questions. While we don’t know what the next days and weeks will bring, I believe the American people derive comfort from your honest no nonsense approach with them.

Proud to be your partner.
Wendy

Wendy Holman
CEO & Co-Founder
Ridgeback Biotherapeutics
www.ridgebackbio.com

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the individual or entity to which it is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this message and any attachments.
Skip:

Thanks for the note. This definitely resonates with me. Such a collaboration could go through DMID (Cassetti and Erbelding) and/or VRC (Mascola). I have copied everyone of this email. We can talk about specifics after we get them involved.

Best,

Tony
It is about 9 to 10% Around 8000 cases and 774 deaths.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, January 23, 2020 8:54 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]
Subject: RE: Coronavirus and Davos

P.S. what was the mortality rate for SARS? I've heard claims of 60% but I thought it was a lot lower than that.

FC

-----Original Message-----
From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, January 23, 2020 8:52 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]
Subject: RE: Coronavirus and Davos

Thanks for all this updated info, Tony. I had a premonition that Lally Weymouth would call on me at the Washington Post luncheon (in front of numerous US Cabinet members, Ivanka, and several heads of state). Sure enough, she did. I think I did a decent job of relating what we currently know about coronavirus, and what we don't know yet.

If there are press calls about what the US is doing, I will refer them to you. I'm cc'ing John.

FC

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 6:56 AM
To: Collins, Francis (NIH/OD) [E]

NIH-002862
Subject: RE: Coronavirus and Davos

Anecdotal data suggest that most transmissions occur when transmitter is late in the infection, i.e. clinically ill. However, some anecdotal data suggest that early transmission does occur to some degree. The man in Seattle who travelled to Wuhan cannot remember coming into contact with anyone who appeared ill. Regarding mAbs, we have them against SARS and MERS and are hoping that there is some cross-reactivity of the anti-SARS Abs with nCov. However, it is difficult at this time to test since we do not yet have isolates of nCov; we only have sequence. As soon as we get isolated we can test.

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] <(b)(6)>
Sent: Thursday, January 23, 2020 5:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: Coronavirus and Davos

Hi again,
Was just part of a discussion with Hatchett, Farrar, WHO rep (Tedros not here), Berkley, Stoffels. Big issue seems to be whether transmissibility happens early or late in the course of infection. Obviously late would be much better for public health measures. Your read on current data?
Any effort on developing MAb at NIH?
PC

Sent from my iPhone
I have gone over this. Please see me about it early next week so that we can finalize it and get it out. Thanks.
Please handle. Thanks.

-----Original Message-----
From: Mark Pasek
Sent: Tuesday, January 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: coronavirus

I am wondering if the complexity of the coronavirus genome invites developing a full-length dsDNA immunogen.

Mark Paul Pasek, PhD
Houston, TX
Sent from my iPhone
Please handle.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-0461  
FAX: (301) 496-4409  
E-mail: fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Frank Diamond <fdiamond@mjh lifesciences.com>  
Sent: Thursday, January 23, 2020 11:22 AM  
To: Fauci, Anthony (NIH/NIAID) [E]  
Subject: Personal Protective Equipment and coronavirus

Dear Doctor,

I would like to your input (if even just a single quote?) about the importance of PPE in light of the coronavirus outbreak for a story that I hope to post to our website today. What are the protocols? Should extra precautions be taken and, if so, what? What's the best sort of equipment? Thanks for any help.

Cordially,

Frank Diamond  
Managing Editor  
Infection Control Today
Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.
Incorrect. My home phone is (b) NOT (b) (6)

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Sunday, January 19, 2020 9:08 PM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E]; Ali, Dalal <Dalal.Ali@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

I don’t see the invite. Please send to live:niaidhelp or niaidhelp@outlook.com.

Dr. Fauci home number is (b) (6)

My cell is (b) (6)

Sent from my iPhone

On Jan 19, 2020, at 9:02 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi David,

These are the numbers we have to call Dr. Fauci. Please, confirm which one should we use:

(b) (6) and (b) (6)

I’m ready now if you prefer to test now. I can see that the invitation I sent you on Skype is still pending. Please, could you confirm you got it?

Please, let me know.

Thanks!

Begoña

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Monday, January 20, 2020 9:59 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>

Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

If you call my cell, I can conference Dr. Fauci in for a test call.

Sent from my iPhone

---

On Jan 19, 2020, at 8:32 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Thanks so much, Patricia!

---

From: Conrad, Patricia (NIH/NIAID) [E]<Dalal.Ali@turner.com>
Sent: Monday, January 20, 2020 9:31 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

David Awwad is the POC for the connection. He will respond.

Sent from my iPhone

---

On Jan 19, 2020, at 8:29 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi Patricia,

I've now taken over from Dalal and will be testing your Skype connection at 9.30 pm ET. I've sent a Skype contact request to Niadithelp from my personal Skype account. Please, let me know if you didn't get it.

Thanks and regards,

Begoña

---

From: Conrad, Patricia (NIH/NIAID) [E]<Dalal.Ali@turner.com>
Sent: Monday, January 20, 2020 2:08 AM
Ok thanks

Sent from my iPhone

On Jan 19, 2020, at 1:06 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Got it – let's test around 9:30pm then.

Adding Begona who will be the one conducting the Skype test.

Thank you all.

From: Conrad, Patricia (NIH/NIAID) [E]  (b) (6)
Sent: Sunday, January 19, 2020 1:04 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C]  (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E]  (b) (6); Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Since this is Skype he will do this from his residence in

Sent from my iPhone

On Jan 19, 2020, at 1:01 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hi Patricia.

Thank you for the below.
The exact taping time is 10pmET.
We can test any time ahead of that. Since he is heading to NIH then we can test shortly before – as I’m sure the connection there is great and it won’t take too long. Around 9:45 pm?

I have received David’s information – thanks again.

Regards,

Dalal

From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Sent: Sunday, January 19, 2020 12:58 PM
To: Ali, Dalal <Dalal.All@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] (b)(6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ali: pls confirm exact interview time. Dr Fauci will be doing the interview from (b)(6) but he works at the national institutes of Health in Bethesda Maryland. Again he will physically be in (b)(6) for this interview.

Backup numbers for him are (b)(6) and cell (b)(6)

David pls provide your cell number as well. My cell is (b)(6)

Please provide CNN studio Number as well.

Please note pronunciation for Dr Fauci is Fow-Chee and it rhymes with grouchy.

Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:41 PM, Ali, Dalal <Dalal.All@turner.com> wrote:

Hello David,

Thank you. I have attached our Skype instructions to this email.
Can you provide the following:

Location: Bethesda?
Time to Test the Skype:
Phone number for set-up:

We appreciate your flexibility and do let me know if you have any further questions.

Regards,

Ms. Dalal Ali
Planning Producer- CNN International

From: Awwad, David (NIH/NIAID) [C] (b) (6)
Sent: Sunday, January 19, 2020 12:37 PM
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) ; Fauci, Anthony (NIH/NIAID) [E] (b) (6) ; Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Skype handle:

Niaidithelp or niaidithelp@outlook.com

Sent from my iPhone

On Jan 19, 2020, at 12:35 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thank you for confirming Dr. Fauci’s availability to do the interview via Skype.

My colleague Dalal will be in touch shortly to confirm all the logistics.

Thank you again,

Hannah
From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Sent: 19 January 2020 17:29
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6); Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] (b)(6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can do this by Skype on his phone. I have added David Awwad here who can give you the Skype connection info. Please include him on all future correspondence. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:18 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10pET.

If it isn’t, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Sent: 19 January 2020 15:34
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6); Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

He will not need a car.

Also-to clarify-this will be a pre tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.
On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That's great – thank you Patricia.

Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 15:12
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone
On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I’ve spoken to show producers and they need Dr Fauci this evening for a pre-tape – sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E]   (b) (6)
Sent: 19 January 2020 14:59
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E]   (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Washington DC.

Sent from my iPhone

On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci’s availability – what CNN studio will he be available from?

I will speak to my producers and confirm availability ASAP.

Best,
Hannah
Dr. Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,

Hannah

Hannah what is the exact live hit time?

Sent from my iPhone
On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you’re well.

I wanted to introduce myself, I’m Hannah Lovejoy and I’m a planning producer for CNN International.

We were hoping that you would be available to join us for a one-on-one interview today (Sunday 19th January)?

We’d like you to discuss the new coronavirus pneumonia which is now known as the Wuhan virus.

More specifically, we’d like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you’re available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, CNN International
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1727 | Cell: [redacted]

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.
Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.
System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

<How to conduct a Skype interview with CNN.pdf>
Zeke:

Good job on this. Sorry I did not get back to you on your e-mail that I am just seeing now. I have been ‘locked’ in the Situation Room for hours over the past 2 days.

Best,
Tony

Ex-Obama health advisor: US needs to ‘stop panicking and being hysterical’ about coronavirus

Published Thu, Jan 30 2020 10:17 AM EST
Jessica Bursztynsky@jbursz

- Americans are too worried about the new coronavirus that’s spreading rapidly across China, former White House health advisor Ezekiel Emanuel told CNBC on Thursday
- “Everyone in America should take a very big breath, slow down and stop panicking and being hysterical,” said Dr. Emanuel.
- “I think we need to put it into context, the death rate is much lower than for SARS,” he added.
US should ‘stop panicking’ about coronavirus, says former Obama health advisor

Americans are too worried about the new coronavirus that’s spreading rapidly across China, former White House health advisor Ezekiel Emanuel told CNBC on Thursday.

“Everyone in America should take a very big breath, slow down and stop panicking and being hysterical,” said Dr. Emanuel, who served during Barack Obama’s presidency. “We are having a little too much histrionics on this.”

Alex Azar, the current secretary of Health and Human Services under President Donald Trump, also said later on CNBC on Thursday that the risk to Americans remains low.

Chinese officials on Thursday increased their confirmed coronavirus cases to nearly 8,000, though some experts believe the number to be much larger. The death toll rose to 170.

Health officials across the world have been putting efforts in place, such as travel restrictions and isolation, to stop the virus from spreading. It was first discovered in the Chinese city of Wuhan in Hubei province in December.

The Centers for Disease Control and Prevention has confirmed five cases of the coronavirus in the United States, with 92 pending tests, as of Wednesday. Other countries around the world are also reporting isolated cases.

“I’m actually pretty confident that we’re going to restrict the spread in the United States and people should remember not to panic,” said Emanuel, University of Pennsylvania’s vice provost for global initiatives. “We need to be a little sober about it, even in China.”

The Wuhan virus, which causes flu-like symptoms, is not spreading through human-to-human contact in America, Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, said on Monday.

But Dr. Mike Ryan, executive director of the World Health Organization’s health emergencies program, said Wednesday that the coronavirus has spread to a handful of people through human-to-human contact outside of China.
The WHO is set to reconvene this week to decide whether to declare the coronavirus a global health emergency.

The new virus has now infected more people in China than were sickened there during the 2002-2003 SARS epidemic. That severe acute respiratory syndrome outbreak, which also originated in China, killed 774 people.

“I think we need to put it into context, the death rate is much lower than for SARS,” Emanuel said.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Ayesha:

Thanks for the note. I have not heard anything about these people and so it would be premature to discuss them. Are they from Wuhan and travelled here? Are they being investigated by the CDC?

Thanks,
Tony

-----Original Message-----
From: Ayesha Khan <Aisha.Khan@FOXTV.COM>
Sent: Sunday, January 26, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Subject: Ayesha from FOX 5

Hello Dr. Fauci,

Reporter Ayesha Khan from FOX 5. Are you by any chance available for another on camera interview regarding three people who are currently being investigated for possibly showing signs of the Coronavirus in Virginia? Two in Central and one in No. Va.

I can be reached on my cell at (b)(6)
Thanks so much!
Ayesha
No. I have never heard of this organization.

Do you think this is a good use of my time?

Begin forwarded message:

Dear Hillary,

I was referred to you by Dr Robert Eisinger. I lead AAPM--American Association for Precision Medicine and we are in a process of creating a coronavirus task force consisting of volunteer physicians, scientists, technologists and innovators. I would like to extend my personal invitation to you to join the task-force or be an advisor to AAPM on this initiative. The task-force consists of experts who have prior experience in dealing with anti-viral drugs, diagnostics and/or have experience in handling disease outbreak.

It is concerning that coronavirus that is creating a chaos in China has now reached Europe and the US. The virus has also been reported in Australia, Thailand, France, Japan, South Korea, Taiwan, Vietnam, Singapore, and Saudi Arabia. As of Monday night, there were nearly 4,500 confirmed cases and 107 deaths. The AAPM coronavirus taskforce will work together to come-up with strategies to contain the disease, new ways to diagnose, and explore opportunities to re-purpose existing drugs to help the community in this global crisis. Also, we are taking this outbreak as an opportunity to learn, to prevent and deal with any future outbreaks.

We would love to have you as a part of this task force. Looking forward to hearing from you.

Sincerely,

Prasun

Prasun J Mishra, PhD
President, American Association for Precision Medicine
Begoña:

Thanks for the note. It was great working with you last night. The precautionary measures that you should take if you go to the higher risk areas are the same as for any other respiratory borne infection such as influenza. You should wash your hands as frequently as possible. If this is not feasible then the alcohol wipes or liquid that are sold in pharmacy would be good to frequently wipe your hands with. You should stay away from "wet" animal markets where they sell live animals and you should make sure that you only eat well-cooked food. In addition, you should avoid very crowded places where there are people who are coughing or who appear ill. Finally, you can wear a mask as you will see many Chinese people wearing.

We get information from the Wuhan authorities on a daily basis. Sometimes it is difficult to know if we are receiving all of the important information on a timely basis, but I believe that the Chinese have been very good in keeping us informed. I hope that this is helpful to you.

Best regards,

Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Thanks so much for your time today for the interview.

I just wanted to check if you could help us with some information. What are the precautionary measures we should take if we were to go to higher risk areas, like Wuhan to cover the story? How should we prepare for that? What protection should we wear?

How often are you getting information from the Wuhan authorities and is this information enough for you to do investigation on the virus?

Thanks so much in advance!

Best regards,

Begoña

---

From: Blanco Munoz, Begoña
Sent: Monday, January 20, 2020 10:30 AM
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Hi Patricia,

The interview will air at some point after 2 am ET, in our show Newsroom.

Thanks and regards,

Begoña

---

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Monday, January 20, 2020 10:27 AM
To: Blanco Munoz, Begoña <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Can you also please let me know what time the piece will air? Thank you

Sent from my iPhone

On Jan 19, 2020, at 9:13 PM, Blanco Munoz, Begoña <Begona.BlancoMunoz@turner.com> wrote:

we'll test out of my personal ID,

I'll talk to you at 9.30 pm ET then
Sent from my Samsung Galaxy smartphone.

-------- Original message --------
From: "Awwad, David (NIH/NIAID) [C]" (b) (6)
Date: 20/01/2020 10:09 (GMT+08:00)
To: "Blanco Munoz, Begona" <Begona.BlancoMunoz@turner.com>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Ali, Dalal" <Dalal.Ali@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>, "Fauci, Anthony (NIH/NIAID) [E]"

Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

I sent a request to live guest. My request is still pending as well.

Sent from my iPhone

On Jan 19, 2020, at 9:02 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi David,

These are the numbers we have to call Dr. Fauci. Please, confirm which one should we use:

(b) (6) and (b) (6)

I'm ready now if you prefer to test now. I can see that the invitation I sent you on Skype is still pending. Please, could you confirm you got it?

Please, let me know.

Thanks!

Begoña

From: Awwad, David (NIH/NIAID) [C] (b) (6)
Sent: Monday, January 20, 2020 9:59 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Ali, Dalal <Dalal.Ali@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

If you call my cell, I can conference Dr. Fauci in for a test call.

Sent from my iPhone
On Jan 19, 2020, at 8:32 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Thanks so much, Patricia!

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) 
Sent: Monday, January 20, 2020 9:31 AM 
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> 
Cc: Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) 
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

David Awwad is the POC for the connection. He will respond.

Sent from my iPhone

On Jan 19, 2020, at 8:29 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi Patricia,

I’ve now taken over from Dalal and will be testing your Skype connection at 9.30 pm ET. I’ve sent a Skype contact request to Niadithelp from my personal Skype account (b) (6) 

Please, let me know if you didn’t get it.

Thanks and regards,

Begoña

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) 
Sent: Monday, January 20, 2020 2:08 AM 
To: Ali, Dalal <Dalal.Ali@turner.com> 
Cc: Awwad, David (NIH/NIAID) [C] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> 
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ok thanks

Sent from my iPhone

On Jan 19, 2020, at 1:06 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Got it – let’s test around 9:30pm then.
Adding Begona who will be the one conducting the Skype test.

Thank you all.

From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Sent: Sunday, January 19, 2020 1:04 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] (b)(6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Since this is Skype he will do this from his residence in (b)(6)

Sent from my iPhone

On Jan 19, 2020, at 1:01 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hi Patricia,

Thank you for the below.
The exact taping time is 10pm ET.

We can test any time ahead of that. Since he is heading to NIH then we can test shortly before – as I'm sure the connection there is great and it wont take too long. Around 9:45 pm?

I have received David's information – thanks again.

Regards,

Dalal

From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Sent: Sunday, January 19, 2020 12:58 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] (b)(6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ali- pls confirm exact interview time. Dr Fauci will be doing the interview from (b)(6) but he works at the national institutes of Health in Bethesda Maryland. Again he will physically be in (b)(6) for this interview.
Backup numbers for him are (b) (6) and cell (b) (6).

David pls provide your cell number as well. My cell is (b) (6).

Please provide CNN studio Number as well.

Please note pronunciation for Dr Fauci is Fow-Chee and it rhymes with grouchy.

Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:41 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hello David,

Thank you. I have attached our Skype instructions to this email.

Can you provide the following:

Location: Bethesda?
Time to Test the Skype:
Phone number for set-up:

We appreciate your flexibility and do let me know if you have any further questions.

Regards,

Ms. Dalal Ali
Planning Producer- CNN International

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Sunday, January 19, 2020 12:37 PM
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNI interview request - TODAY (Sunday 19th January)

Skype handle:

Niaidithelp or niaidithelp@outlook.com
On Jan 19, 2020, at 12:35 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thank you for confirming Dr. Fauci's availability to do the interview via Skype.

My colleague Dalal will be in touch shortly to confirm all the logistics.

Thank you again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 17:29
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can do this by Skype on his phone. I have added David Awwad here who can give you the Skype connection info. Please include him on all future correspondence. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:18 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10pET.

If it isn't, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.
He will not need a car.

Also to clarify this will be a pre tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That’s great – thank you Patricia.

Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone
On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I’ve spoken to show producers and they need Dr Fauci this evening for a pre-tape – sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

---

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 14:59
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Washington DC.

Sent from my iPhone

---

On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci’s availability – what CNN studio will he be available from?
I will speak to my producers and confirm availability ASAP.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 14:39
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 13:57
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Hannah what is the exact live hit time?
On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you’re well.

I wanted to introduce myself, I’m Hannah Lovejoy and I’m a planning producer for CNN International.

We were hoping that you would be available to join us for a one-on-one interview today (Sunday 19th January)?

We’d like you to discuss the new coronavirus pneumonia which is now known as the Wuhan virus.

More specifically, we’d like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you’re available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, CNN International
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: + (816) 693 1777
the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its
contents to anyone. Please note we reserve the right to monitor all e-mail communication through our
internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks
International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited
(Company Number 2802926) and Cable News International Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at Turner House, 16 Great
Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended
exclusively for the addressee. The views expressed may not be official policy, but the personal views of
the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its
contents to anyone. Please note we reserve the right to monitor all e-mail communication through our
internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks
International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited
(Company Number 2802926) and Cable News International Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at Turner House, 16 Great
Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended
exclusively for the addressee. The views expressed may not be official policy, but the personal views of
the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its
contents to anyone. Please note we reserve the right to monitor all e-mail communication through our
internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
System Inc and are used under licence.
Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

<How to conduct a Skype interview with CNN.pdf>
Let us try to do this.

From: Tamera Coleman <tcoleman@gingrich360.com>
Sent: Thursday, January 30, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (o)>
Subject: Guest for Coronavirus podcast episode

Hello Dr. Fauci -- My name is Tamera. I handle the booking for Newt Gingrich’s Podcast, Newt’s World. It is a non-partisan show where Newt gives historical context behind people and events. We launched last February and have 2.5 millions downloads to date with new episodes each Sunday. We are working on an episode of the podcast centered around “The Coronavirus” where you might discuss The Global viruses [Novel Coronavirus 2019 (nCoV-2019),SARS,MERS,Bird Flu] and What Can Be Done to Prevent the Next Epidemic?

If interested, Newt would interview you on Thursday, February 6th, where you would call in to the studio. The podcast would air Sunday, February 9th.

Interview Times:
8:30-9:30; 9:30-10:30; 10:30-11:30 (EST)

Looking forward to hearing back soonest, as we would like to confirm booking as much in advance as possible.

Thanks much
Tamera
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 22:07:22 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Our 1:1 tomorrow

Francis:
Thanks for the note. I am swamped with coronavirus issues. Let us do the debrief about the IC meeting at a later time.
Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] <[redacted]>
Sent: Sunday, January 26, 2020 5:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted]>
Subject: Our 1:1 tomorrow

Hi Tony,

We are scheduled to meet for a half hour tomorrow, and there are lots of things to discuss – like coronavirus. You must be running in ten directions at once. I will be glad to go over a list of current issues, but I will leave it to you whether this is a good day for you to give me the feedback about the review of the NIH Director’s performance, or whether it’s better to wait until a later day for that.

Francis
I would be happy to. I am really tied up with coronavirus and the deadline is Friday. What do I need to do? Please work with my Special Assistant, Patty Conrad on this.

From: Hotez, Peter Jay
Sent: Tuesday, January 28, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Soriano Osejo, Douglas; Conrad, Patricia (NIH/NIAID) [E]
Subject: NAM nomination for Alison Galvani

Dear Tony, I’m

Thanks! Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar
Baylor College of Medicine

Texas Children’s Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children’s Hospital Center for Vaccine Development

University Professor
Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study
Senior Fellow, Scowcroft Institute of International Affairs
Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University
Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: 
Twitter: 
Skype: 
Website: https://peterhotez.org/
Amazon Author Center: https://www.amazon.com/Peter-J-Hotez/e/B001HPIC48
Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/
Sent from my iPhone
Very nicely done! 😊

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone:  
FAX: (301) 496-4409  
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Let us discuss.

Dr. Fauci....

Sorry to bother you on a holiday. Dr. LaPock is off today, but I'm trying to help our team in China covering the Coronavirus story. As you I know, Chinese epidemiologist Zhong Nanshan, said two cases in Guangdong Province were confirmed to be people-to-people transmission. He also said 14 medical workers were infected. I'm reaching out to see if there is any possibility at all of a brief interview with you today. We're looking for some context as to why person to person spread is significant.

We could send a crew to you or we would also do it as a Skype interview if that works for you. Alternately, if you can give us your thoughts on this development in an e-mail, we would quote you in our story..

Again, my apologies for reaching out on a holiday, thanks for your consideration.

Kevin
Kevin Finnegan
Medical Producer

CBS Evening News with Norah O'Donnell

P. 212.975.7486
C. [redacted]

kpf@cbsnews.com
FYI

From: Megan Schartner <MSchartner@scgcorp.com>
Sent: Thursday, January 30, 2020 9:46 PM
To: Deatrick, Elizabeth (NIH/NIAID) [C] ; Pekoc, Ken (NIH/NIAID) [E]
Conrad, Patricia (NIH/NIAID) [E] ; Fauci, Anthony (NIH/NIAID) [E]
(6); Hoffman, Hillary (NIH/NIAID) [E]
(6); Oplinger, Anne (NIH/NIAID) [E]
(6); Rancourt, Anne (NIH/NIAID) [E]
(6); Stover, Kathy (NIH/NIAID) [E]
(6); NIAID OD AM <NIAIDODAM@naitd.nih.gov>; Awad, David (NIH/NIAID) [C]
(6)
Cc: Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E]
(6); Meylin Correa <mcorreia@scgcorp.com>; Lindsey Beall <lbeall@scgcorp.com>; Marcia Bache
<mbache@scgcorp.com>
Subject: Clip of Dr. Fauci on PBS NewsHour

Good evening,

Below is a clip of Dr. Fauci on PBS NewsHour this evening discussing the coronavirus.

https://app.criticalmention.com/app/#/clip/public/5a05811b-ad42-4d4c-a5b3-ac46560a46bf?show_sentiment=false

Thank you,
Megan

From: Critical Mention <do-not-reply@criticalmention.com>
Sent: Thursday, January 30, 2020 9:42 PM
To: Megan Schartner
Subject: Critical Mention: Megan Schartner has shared a TV Mention with you

Megan Schartner has shared a TV Mention with you!

From Megan Schartner (mschartner@scqcorp.com)

View Mention

PBS NewsHour
Genre: News
Program Name  PBS NewsHour  
Source  KETA - Network  
Market  DMA: 43 Oklahoma City, OK  
Time  Jan 30, 2020 7:29 PM EST  
Clip Length  06:19.947

>> woodruff: we return now to the latest on the coronavirus outbreak. william brangham has a closer look at today's developments. >> brangham: that's right, judy, we've seen this past week the rapid spread of this virus in china, and its escape to at least 14 other nations. as we reported before, the w.h.o. has declared this a global public health emergency, and we've now seen the first confirmed person-to-person transmission here in the u.s. for a closer look at what this all means, we turn to dr. anthony fauci. he's the director of the national institute of allergy and infectious diseases at the n.i.h. dr. fauci, welcome back to the news hour. we've seen this first case, a 60-something year old woman who went to china, got the virus, came home and apparently infected her husband once she was back here. we know how viruses operate, especially among people who are living together. on some level this is to be expected, but people seeing this news, what would you say to them for their alarm and their concern about this? >> you know, i think you just said it. this is something to be expected when you have someone who in very close contact with another individual that is infected. it is not surprising that there's transmission. the thing that would be of concern and that we're watching very carefully is what you call sustained transmission from one person to another to another to another. the system here right now is that that individual who was just recently infected from a person who was actually infected in china, came here, and then infected a close partner, that individual is now under isolation, and the contacts with whom that person came into, those individuals are now being traced. so the public health system is now on
top of that. what the concern globally is, the rapid sustained person-to-person-to-
person transmission, which is going on right now, certain to a great degree in china,
and the reason the w.h.o. declared this a public health emergency of international
concern is because in other countries outside of china, we’re starting to see that
sustained transmission from person to person to person to person. that’s the thing
you need to be concerned about. but right now the risk in the united states is still low.
but with the same breath i say that, i say we are taking this very, very seriously as
public health officials and scientists. >> brangham: in your press conference earlier
this week, you kept stressing the need for more information, for more data, for more
samples to come out of china. are you getting the cooperation and the information
and the sharing you need from chinese officials to best do your job? >> you know,
the answer is yes, but i think we can do better. if you compare the transparency
during the sars outbreak in 2002, everyone realized that they were egregiously non-
transparent and that delayed things a long time. that’s different now. they really are
being open, but what we would like to see is the actual data and the patterns of
disease that are going on there ourselves, because what happens there will inform
us better as to what our policies will be here. so it looks like we’re getting many that
direction. the w.h.m.o. -- w.h.o. is getting a group put together to go there, hopefully
including us, that would actually take a first hand, on-the-ground look at the data. >>
brangham: there is a fair amount of modeling coming out of hong kong and other
parts of the world looking at the current spread and indicating that this may turn into
a real global pandemic. do you weave that’s true, or do you still think it’s too early to
make that call? >> no, i think you have to be realistic and say it is possible that it
could turn into a global pandemic. that’s the reason why we’re doing everything we
can to prevent that. i think to deny the possibility would be unrealistic. and that’s the
reason why we’re preparing for the worst. whether it’s going to happen, we have no
way of predicting what the odds of that are. the chinese are doing rather dramatic
things to try and contain that within their own country. the idea of locking down 50
million people to prevent their from going in and out of certain areas is a very, very
dramatic way to try and contain that. what we’re doing here is the typical, classical
public health measure, trying the keep people who aren’t affected out of the country, and
then if someone does get in, to isolate them and to prevent them from infecting
others. hopefully those public health measures will work. but we still need to prepare
for the worst and we know we are taking this and the general public of the united
states and the world should know that we are taking this very, very seriously. >>
brangham: in just the short bit of time we have left, i imagine that this has got to be
difficult for you, dealing with these fears about handful of virus cases here in the u.s.
when we have another virus, the influenza virus, that has already sickened millions
of americans. that’s taken 8,000 temperature’s lives here in this country alone. how
do you help americans balance those concerns and risks over the fear of a virus
coming here versus the one we already have? >> well, i think we have been through
this many times in so many other situations. the fear of the unknown and what might
happen almost always supersedes the concern of something that actually is
happening and causing a lot of damage. and you’re absolutely correct. we are in the
middle of a flu season, an we have more disease and death from flu than even, you

NIH-002912
know new york some countries even have with this outbreak, so the issue is we should concentrate on protecting ourselves from influenza, which we know is patterned at the same time as we prepare for something that we’re in the familiar with, because it’s a brand-new infection. it’s a balance. >> branham: anthony fauci, thank you.
Elizabeth:

Aluvia is also known as Kaletra. It is a combination of two anti-HIV drugs: lopinavir and ritonavir. It was observed in non-controlled trials (historical control) in SARS to have some degree of benefit. Given the fact that there are no proven effective drugs to treat this coronavirus, it is understandable that they are using Aluvia/Kaletra on a compassionate basis. If someone is seriously ill with the virus, there is little down-side to using it. It may not help, but it unlikely will hurt.

Best,
Tony

-----Original Message-----
From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Sunday, January 26, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: A question from a colleague

Tony – thanks so much for chatting earlier today… a colleague of mine would love your thoughts on this… Thanks Elizabeth

https://www.reuters.com/article/us-china-health-abbvie-hiv-idUSKBN1ZP0QK
I attended the DLG meeting via telephone.
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [__] (b) (6)
FAX: (301) 496-4490
E-mail: [__] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Dear Disaster Leadership Group (DLG) Members,

The purpose of this email is to confirm your attendance for the upcoming meeting on [DATE].

Please confirm your attendance or any changes in your availability by [RESPONSE DEADLINE].

[Please provide any additional details or agenda items for the meeting if relevant.]

Best regards,

[Your Name]
[Your Title]
Thank you to everyone who participated in today’s 2020 Novel Coronavirus DLG meeting. Please remember to confirm your attendance, whether in the room or on the call, by emailing the DLGDESK resource mailbox at DLGDESK@hhs.gov.

Respectfully,

Kelsey Donnelly (CTR)
Jr. Management Analyst, Avshka Inc.
Office of the Assistant Secretary for Preparedness and Response
Office of Strategy, Policy, Planning, and Requirements